Moderate to severe atopic dermatitis research hub
7 indexed studies · 5 currently recruiting
- recruitingTherapeutic confirmatory (Phase III)
B7451015 - A PHASE 3 MULTICENTER, LONG-TERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB, WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS
This study looks at a medicine called Abrocitinib (also known as Cibinqo) for people aged 12 and over with moderate to severe eczema. It wants to see if the medicine works well and is safe over a long time, sometimes used with regular skin creams.
Poland · Hungary · Spain - recruitingTherapeutic exploratory (Phase II)
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis
This study is testing a new medicine, JNJ-95475939, for adults who have moderate to severe eczema (atopic dermatitis). Researchers want to see if it helps improve skin symptoms compared to a dummy medicine or an existing treatment called Dupixent.
Spain · Poland · Germany - recruitingTherapeutic exploratory (Phase II)
A Randomized, Double-Blind, Placebo-Controlled Phase 2a Proof of Concept Study Evaluating the Safety and Efficacy of ADX-914 in Subjects with Moderate to Severe Atopic Dermatitis
This study is testing a new medicine, ADX-914, for people with moderate to severe eczema (atopic dermatitis). It's checking if the medicine is safe and if it helps improve skin symptoms compared to a dummy pill.
Poland - active not recruitingPHASE3
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
This study is looking at a new medicine called nemolizumab for people with moderate to severe eczema. It aims to understand how safe and effective the medicine is over a long period. Participants would have been in a previous nemolizumab study.
United States · Australia · Austria - recruiting
TREATgermany: German National Clinical Registry for Patients With Moderate-to-severe Atopic Dermatitis
This study, called TREATgermany, is creating a detailed record of people in Germany with moderate-to-severe eczema (atopic dermatitis). It aims to understand how existing treatments are used and how well they work over time, especially in children and teenagers, and to gather information for future research.
Germany - recruitingPHASE1
A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
This study is testing a new oral medication, SYX-5219, for moderate to severe eczema (atopic dermatitis). It aims to check the drug's safety, how well it's tolerated, and how it moves through the body in both healthy people and those with eczema.
United States · Bulgaria · Denmark - authorisedTherapeutic use (Phase IV)
A Phase IV, non-randomized, open-label multinational trial to assess the mechanism of action for Lebrikizumab in moderate-to-severe atopic dermatitis
This study looks at how a new medicine, Ebglyss, works for people with moderate to severe eczema. Researchers will examine changes in skin samples over time to understand its effects at a very detailed level.
Germany